Biogen (MEX:BIIB) 3-Year Share Buyback Ratio : 0.30% (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Biogen 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Biogen's current 3-Year Share Buyback Ratio was 0.30%.

The historical rank and industry rank for Biogen's 3-Year Share Buyback Ratio or its related term are showing as below:

MEX:BIIB' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -35.8 Med: 4.15 Max: 33.7
Current: 0.3

During the past 13 years, Biogen's highest 3-Year Share Buyback Ratio was 33.70%. The lowest was -35.80%. And the median was 4.15%.

MEX:BIIB's 3-Year Share Buyback Ratio is ranked better than
82.13% of 677 companies
in the Drug Manufacturers industry
Industry Median: -2.2 vs MEX:BIIB: 0.30

Competitive Comparison of Biogen's 3-Year Share Buyback Ratio

For the Drug Manufacturers - General subindustry, Biogen's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biogen's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Biogen 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Biogen (MEX:BIIB) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Biogen 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Biogen's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

BIIB:USA 1BIIB:Italy 0R1B:UK IDP:Germany IDP:Germany IDP:Germany IDP:Germany BIIB:Chile BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.